Literature DB >> 27712737

Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System.

Mohammed K Rashid1, Nita Guron2, Jordan Bernick3, George A Wells4, Melissa Blondeau3, Aun-Yeong Chong3, Alexander Dick3, Michael P V Froeschl3, Chris A Glover3, Benjamin Hibbert3, Marino Labinaz3, Jean-François Marquis3, Christina Osborne3, Derek Y So3, Michel R Le May5.   

Abstract

OBJECTIVES: This study investigated the safety and efficacy of a pharmacoinvasive strategy compared with a primary percutaneous coronary intervention (PCI) strategy for ST-segment elevation myocardial infarction (STEMI) in the context of a real-world system.
BACKGROUND: Primary PCI continues to be the optimal reperfusion therapy; however, in areas where PCI centers are not readily available, a pharmacoinvasive strategy has been proposed.
METHODS: The University of Ottawa Heart Institute regional STEMI system provides a primary PCI strategy for patients presenting within a 90-km radius from the PCI center, and a pharmacoinvasive strategy for patients outside this limit. We included all confirmed STEMI patients between April 2009 and May 2011. The primary efficacy outcome was a composite of mortality, reinfarction, or stroke and the primary safety outcome was major bleeding.
RESULTS: We identified 236 and 980 consecutive patients enrolled in pharmacoinvasive and primary PCI strategies, respectively. The median door-to-needle time was 31 min in the pharmacoinvasive group and the median door-to-balloon time was 95 min in the primary PCI group. In a multivariable model, there was no significant difference in the primary efficacy outcome (odds ratio: 1.54; p = 0.21); however, the propensity for more bleeding with a pharmacoinvasive strategy approached statistical significance (odds ratio: 2.02; p = 0.08).
CONCLUSIONS: Within the context of a STEMI system, a pharmacoinvasive strategy was associated with similar rates of the composite of mortality, reinfarction, or stroke as compared with a primary PCI strategy; however, there was a propensity for more bleeding with a pharmacoinvasive strategy.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ST-segment elevation myocardial infarction; pharmacoinvasive strategy; primary PCI; regional STEMI program

Mesh:

Substances:

Year:  2016        PMID: 27712737     DOI: 10.1016/j.jcin.2016.07.004

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

1.  The relationship between total ischemic time and mortality in patients with STEMI: every second counts.

Authors:  Umair Khalid; Hani Jneid; Ali Emin Denktas
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 2.  Stroke Complicating Acute ST Elevation Myocardial Infarction-Current Concepts.

Authors:  Monika Bhandari; Pravesh Vishwakarma; Rishi Sethi; Akshyaya Pradhan
Journal:  Int J Angiol       Date:  2019-09-20

Review 3.  Unmet goals in the treatment of Acute Myocardial Infarction: Review.

Authors:  Alejandro Farah; Alejandro Barbagelata
Journal:  F1000Res       Date:  2017-07-27

4.  Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries.

Authors:  Sameer Mehta; Christopher B Granger; Timothy D Henry; Cindy Lee Grines; Alexandra Lansky; Ivan Rokos; Roberto Botelho; Andreas Baumbach; Sundeep Mishra; Tan Huay Cheem; Damras Tresukosol; Robaayah Zambahari; Alexandra Ferré; Marco Castillo
Journal:  Indian Heart J       Date:  2017-01-10

5.  Rescue PCI in the management of STEMI: Contemporary results from the Melbourne Interventional Group registry.

Authors:  Himawan Fernando; Diem Dinh; Stephen J Duffy; Angela Brennan; Anand Sharma; David Clark; Andrew Ajani; Melanie Freeman; Karlheinz Peter; Dion Stub; Chin Hiew; Christopher M Reid; Ernesto Oqueli
Journal:  Int J Cardiol Heart Vasc       Date:  2021-03-15

6.  Fibrinolysis Therapy Combined with Deferred PCI versus Primary Angioplasty for STEMI Patients During the COVID-19 Pandemic: Preliminary Results from a Single Center.

Authors:  Jing Nan; Shuai Meng; Hongyu Hu; Ruofei Jia; Zening Jin
Journal:  Int J Gen Med       Date:  2021-01-19

7.  Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy.

Authors:  Kaiyin Li; Bin Zhang; Bo Zheng; Yan Zhang; Yong Huo
Journal:  Front Cardiovasc Med       Date:  2022-03-17

8.  The impact of systems-of-care on pharmacoinvasive management with streptokinase: The subgroup analysis of the TN-STEMI programme.

Authors:  Deep Chandh Raja; Vijayakumar Subban; Suma M Victor; George Joseph; Viji Samuel Thomson; Kumaresan Kannan; Justin Paul Gnanaraj; Ganesh Veerasekar; Jose G Thenpally; Nandhini Livingston; Brahmajee K Nallamothu; Thomas Alexander; Ajit S Mullasari
Journal:  Indian Heart J       Date:  2017-07-18

9.  Efficacy and Safety of Pharmacoinvasive Strategy Compared to Primary Percutaneous Coronary Intervention in the Management of ST-Segment Elevation Myocardial Infarction: A Prospective Country-Wide Registry.

Authors:  Mohammad Zubaid; Haitham Khraishah; Barrak Alahmad; Wafa Rashed; Mustafa Ridha; Fahad Alenezi; Mohamad Aljarralah; Khalid Al-Marri; Mohammad Almutairi; Khalid Althalji; Abdulhamied Alfaddagh
Journal:  Ann Glob Health       Date:  2020-02-05       Impact factor: 2.462

10.  Comparative Effectiveness of Reperfusion Strategies in Patients with ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK) Trial.

Authors:  Haitham Khraishah; Barrak Alahmad; Eric Secemsky; Michael N Young; Ahmed ElGuindy; Mark J Siedner; Mohamad Kassab; Dhaval Kholte; Khuzeima Khanbhai; Mohamed Janabi; Kevin Kennedy; Mazen S Albaghdadi
Journal:  Glob Heart       Date:  2020-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.